MedTrace Logo

Evaluation of Plasma Non-coding RNAs as Biomarkers in Coronary Heart Disease

NCT02751060 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 4000

Last updated 2024-04-10

No results posted yet for this study

Summary

The purpose of this study is to determine whether the expression level of miR-320a are effective as biomarker in evaluating the diagnosis, prognosis and treatment effects of coronary heart disease.

Conditions

  • Coronary Disease

Interventions

OTHER

No intervention

Sponsors & Collaborators

  • Tongji Hospital

    lead OTHER

Principal Investigators

  • Dao Wen Wang, Doctor · Tongji Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02751060 on ClinicalTrials.gov